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Introduction 
 
The Indianapolis Coalition for Patient Safety, Inc. (ICPS) provides a forum for Indianapolis- 
area hospitals to share information about best practices and work together to solve patient 
safety issues. A free standing non-profit, ICPS is comprised of chief executive, medical, 
nursing, quality/safety and pharmacy leaders from the six major health-systems located in 
Indianapolis: Community Health Network, Eskenazi Health, Franciscan Health Indianapolis, 
Indiana University Health, Richard L. Roudebush VA Medical Center, and St. Vincent. While 
competitors in the market-place, hospital leaders have come together to promote patient 
safety. Coalition hospitals pool their expert resources to accelerate patient safety 
improvements through community-wide efforts. 
 
The ICPS has historically achieved accelerated outcomes by sharing resources, 
performance targets, accountability, and learning. Using subject matter experts from 
Coalition hospitals, Coalition-wide multidisciplinary teams are formed. ICPS members 
undertake projects that focus on patient-centered strategies to improve safety. 
 
In 2013, The ICPS Contrast Media Usage and Exposure Workgroup was formed to review, 
define, assess and implement best practices regarding the use of intravascular iodinated 
contrast media (CM) in diagnostic and interventional procedures with respect to the 
associated risk of contrast media-induced nephropathy (CIN) and other adverse events. The 
interdisciplinary workgroup consisted of radiologists, cardiologists, nephrologists, nurses, 
technologists, pharmacists and patient safety experts. The workgroup met regularly to 
review published best practices and current practices within each member health-system. 
The workgroup focused on opportunities to improve patient safety within represent health-
systems and emphasized consensus-based recommendations aimed at reducing intra-
institutional variability.  Based on current literature, best practices, and professional 
experience, the workgroup created these recommendations for safe use of intravenous 
iodinated contrast media. These recommendations do not replace sound clinical judgment or 
other published guidelines. 
 
Early in the process the group identified discordance among the best practice statements 
published by national organizations of the represented specialties (cardiology, nephrology, 
radiology.) The workgroup also identified discordance between the national best practice 
statements and subsequently published literature. As a result, where discordance existed, 
the workgroup ultimately constructed a summative consensus statement describing the 
current evidence-supported, best-practices based on a systematic review for CM usage and 
exposure, specific to the risks related to intravascular contrast media administration 
including: patient screening and risk-stratification, preventive measures, electronic health 
record enhancements aimed at improving patient safety, and other adverse events. We 
employed the search phrase described in Table 1 to identify the body of CIN literature which was 
the major focus of this effort.  
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Table 1. Basic search phrase for CIN in OVID 
1 acute kidney injury.mp. or exp Acute Kidney Injury/ 
2 acute renal failure.mp. 
3 exp Kidney Diseases/ 
4 kidney diseas$.mp. 
5 exp Nephritis/ or nephritis.mp 
6 (nephropa$ or nephrotox$).mp. 
7 1 or 2 or 3 or 4 or 5 or 6 
8 acute kidney failure.mp. 
9 exp Kidney/in, de, pd, to, ae [Injuries, Drug Effects, 
Parmacology, Toxicity, Adverse Effects] 
10 (ARF or AKF).mp. 
11 ((impair$ or damag$ or acute$) adj2 (renal$ or 
kidney$)).mp. 
12 (acute kidney insuffici$ or acute renal insufficie$).mp. 
13 7 or 8 or 9 or 10 or 11 or 12 
14 contrast associated nephropathy.mp. 
15 contrast associated nephro$.mp. 
16 contrast nephropa$.mp. 
17 radiocontrast nephropathy.mp. 
18 contrast nephroto$.mp. 
19 radiocontrast nephrotox$.mp. 
20 radiocontrast induced nephropathy.mp. 
21 ((nephropa$ or nephrotox) and (contrast or 
media)).mp. 
22 CIN.mp. 
23 (kidney$ or renal$ or contrast$).mp. and 22 
24 14 or 15 or 16 or 17 or 18 or 19 or 20 or 23 
25 21 or 24 
26 13 or 22 or 23 or 25 
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List of Abbreviations 
 
ACR = American College of Radiology 
ACC = American College of Cardiology 
ACEi = angiotensin converting enzyme inhibitors 
AHA = American Heart Association 
ASN = American Society of Nephrology 
ARB = angiotensin receptor blockers 
CT = Computed Tomography 
CIN = contrast media-induced nephropathy 
CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration 
CM = iodinated, intravascular contrast media 
CPOE = computerized physician order entry 
eGFR = estimated glomerular filtration rate 
EHR = electronic health record 
eMAR = electronic medication administration record 
ICPS = Indiana Coalition for Patient Safety 
IV = intravenous 
LOCM = low-osmolar contrast media 
MDRD = Modification of Diet Renal Disease 
MRI = magnetic resonance imaging 
NAC = n-acetylcysteine 
NSAID = non-steroidal anti-inflammatory drugs 
NKDEP = National Kidney Disease Education Program 
NKF = National Kidney Foundation 
STEMI = ST-elevation myocardial infarction 
SCAI = Society for Cardiovascular Angiography and Interventions 
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Summary of Recommendations 
I. Screening 
1. Risk Factor Screening 
Consensus Statement I-1 (page 18-19) 
A. The workgroup recommends screening procedures that identify patients with the following 
independent risk factors for contrast induced nephropathy (CIN): chronic kidney disease 
(CKD), diabetes mellitus, age ≥75 years, and congestive heart failure. 
B. The work group recommends using a minimum threshold for estimated glomerular filtrate 
rate (eGFR) of <40 ml/min/1.73m2 to define renal insufficiency/CKD. The workgroup also 
recognizes that data support a widened threshold of <60 ml/min/1.73m2. 
C. For patients with risk factors, who do receive iodinated, intravascular contrast media 
(CM), the workgroup recommends a follow-up evaluation and screening for CIN within 72 
hours in the inpatient setting and within 7 days in the ambulatory setting. 
 
2. Renal Function Screening 
Consensus Statements I-2 and I-3 (page 15-16) 
A. The workgroup recommends using eGFR to identify renal insufficiency/CKD. The 
Modification of Diet in Renal Disease (MDRD) study equation, the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI), and the Cockcroft-Gault equation are all acceptable 
methods to determine eGFR rate using measured serum creatinine. 
B. The workgroup supports a screening serum creatinine to assess eGFR within 30 days prior 
to exposure to CM in the ambulatory setting and within 48 hours in the inpatient setting. 
C. The workgroup supports assessment of eGFR in patients with a history of renal dysfunction. 
D. While less clearly supported by current literature, eGFR screening appears reasonable in 
the patients with the following conditions: age ≥ 60 years, hypertension and/or prior 
kidney surgery. 
E. The workgroup also recommends referral of patients at increased risk of CIN for follow-up 
assessment of eGFR within 72 hours in inpatients and within 1 week in outpatients 
following CM administration. 
 
3. Emergency Exception 
Consensus Statement I-4 (page 16) 
A. For specific emergent indications, pre-procedural screening and lengthy treatment 
measures, including serum creatinine screening for assessment of eGFR, may delay access 
to emergent diagnostic and interventional procedures and are of limited benefit. Examples 
include: 1) ST elevation myocardial infarction (STEMI) requiring emergent cardiac 
catheterization; 2) emergent evaluation for thrombolysis for acute cerebral vascular 
accident (“stroke one” or “code stroke”); 3) acute vascular complications requiring 
emergent intervention such as aortic dissection, aortic aneurysm rupture, acute limb 
ischemia, and mesenteric ischemia; and 4) indications for potentially life or limb 
threatening conditions. 
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II. Prevention 
1. Peri-procedural Hydration 
Consensus Statement II-1 (page 17-18) 
A. Peri-procedural intravenous hydration with normal saline and, if appropriate, post- 
procedural oral hydration, is recommended for patients at increased risk of CIN. 
Please refer to consensus statement II-01 for hydration recommendations. 
 
2. N-Acetylcysteine (NAC) 
Consensus Statement II-2 (page 19) 
A. There are insufficient data to support the use of NAC to prevent CIN in patients at 
risk, including patients who are volume-sensitive. 
 
3. Sodium Bicarbonate 
Consensus Statement II-3 (page 19-20) 
A. There are insufficient data to support the use of sodium bicarbonate to prevent CIN 
in patients at risk, including patients who are volume-sensitive. 
 
4. Post-procedural Dialysis 
Consensus Statement II-4 (page 20) 
A. Post-procedural dialysis for the prevention of CIN in patients with CKD is of limited 
effectiveness and is potentially harmful. 
 
5. Iso-osmolar Contrast Media 
Consensus Statement II-5 (page 20-21) 
A. There are insufficient data to support the use of iso-osmolar CM as an alternative to 
contemporary low-osmolar, non-ionic agents to prevent CIN in patients at risk, 
including patients who are volume-sensitive. 
 
6. Cessation of Concurrent Medications 
Consensus Statements II-6 and II-7 (pages 21-23) 
A. There are insufficient data to recommended cessation or restriction of the 
medications reviewed by the workgroup (detailed in consensus statement II-6) 
prior to or following CM exposure. 
B. The workgroup recommends selective discontinuation of metformin for a 
minimum of 48 hours after CM administration for patients with the following 
conditions: CKD, liver disease, alcohol abuse, cardiac failure, myocardial or 
peripheral muscle ischemia, and/or sepsis or severe infection. In patients at 
increased risk of acute kidney injury, discontinuation of metformin is 
recommended along with an assessment of renal function and ongoing risk for 
progressive renal dysfunction, prior to resuming metformin use. 
 
7. Minimizing Contrast Media Exposure 
Consensus Statement II-8 (page 23) 
A. The workgroup recommends recurring institution and site-level reviews of imaging and 
interventional protocols for adherence to the ACR Appropriateness Criteria® and the 
ACCF/AHA Guidelines with specific attention to the inclusion of protocols that reduce or 
eliminate CM exposure in patients at increased risk of CIN. 
B. The workgroup supports institutional efforts to identify and evaluate emerging imaging or 
interventional techniques that avoid or limit CM exposure in patients at increased risk of 
CIN. 
C. The work group supports the referral of selected patients at increased risk of CIN to 
institutions or sites where appropriate non-CM or reduced-CM alternatives are 
performed with demonstrated reliability. 
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III. Electronic Health Record (EHR) Recommendations 
1. Reporting Contrast Media Administration 
Consensus Statement III-1 (page 24) 
A. The workgroup recommends recording of CM administration, including date, time, 
type/concentration, volume, and route of administration, in a central location in the 
EHR that is accessible to all departments within the health system. 
B. The workgroup recommends the development of interfaces with the central EHR and 
existing setting-specific electronic systems. These interfaces should allow for an 
automatic entry into the central EHR and should minimize additional re-entry by end 
users. (Regulatory processes reviewed in consensus statement III-1). 
 
2. Computer Order Entry 
Consensus Statement III-2 (page 24-25) 
A. When the use of CM is planned for non-emergent cardiovascular, interventional 
radiology or other interventional procedures, the pre- procedural patient evaluation 
should include specific screening for risk factors for CIN (consensus statements I-1, I-2, 
I-3 and I-4) and for exposures to CM within 1 week (consensus statement III-1). In cases 
where the interventionalist is not directly assessing these factors, institutions should 
identify specific processes for communicating the presence of one or more CIN risk-
factors to the interventionalist performing the procedure. 
B. For diagnostic radiology imaging studies, institutions should develop targeted, 
automatic alerts that can be integrated in CPOE systems. Such alerts should be 
generated based on information available in the EHR (e.g. problem lists, medication 
records, etc.). The alert should provide the following information to the 
ordering/referring provider: 1) That the patient is at increased risk of CIN; and 2) Real- 
time contact information for the appropriate diagnostic radiologist(s). Institutions 
should also have a process for ensuring that contact information is correct, up-to-date, 
and includes backup contacts. 
C. The workgroup recommends that each CPOE order structure for diagnostic radiology 
imaging studies should prompt the ordering/referring provider to describe the specific 
clinical indications and/or clinical concern(s) for the study. General procedural or 
diagnostic code categories do not meet this recommendation. 
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IV. Management of Intravenous Contrast Media Extravasation and Allergic 
Reactions 
 
1. Extravasation 
Consensus Statement IV-1 (page 26) 
A. Identification – Patients may complain of swelling, tightness, stinging or burning at the 
extravasation site. Additionally the site may appear edematous, erythematous, and be tender 
to palpation. 
B. For management the workgroup recommends elevating the affected extremity above the 
level of the heart, application of cold compresses, and frequent clinical assessments for 
several hours after an extravasation. The workgroup does not recommend  aspiration of the 
extravasated contrast media and does not recommend local injection of corticosteroids or 
hyaluronidase based on a lack of evidence of efficacy 
 
2.  Allergic Reactions 
Consensus Statement IV-2 (page 26-27) 
A. For classification of reactions, the workgroup recommends appropriate assessment of 
contrast reactions as treatments and level of care are determined based on the classification 
of the reaction. Unlike most medication allergy classifications, both moderate and severe 
contrast allergic reactions may require intervention. Refer to Table 2 for descriptions of 
allergic reaction presentations. Delayed adverse reactions most commonly present as 
urticarial, a persistent rash, or generalized exanthematous pustulosis. Non-cutanous 
reactions include nausea, vomiting, fever, drowsiness, and headache. Severe delayed 
reactions are rare.  
 
Table 2: Contrast Allergic Reaction Presentations 
 Mild Moderate Severe 
A
ll
er
gi
c-
L
ik
e*
 
 Limited: urticaria, 
pruritus, cutaneous 
edema, itchy/scratchy 
throat 
 Nasal congestion 
 Sneezing, conjunctivitis, 
rhinorrhea 
 Diffuse: urticaria, 
pruritus, erythema 
 Facial edema without 
dyspnea 
 Throat tightness or 
hoarseness without 
dyspnea 
 Wheezing, 
bronchospasm with mild 
to no hypoxia 
 Diffuse edema or facial 
edema with dyspnea 
 Diffuse erythema with 
hypotension 
 Laryngeal edema with 
stridor and/or hypoxia 
 Wheezing, bronchospasm  
 Significant hypoxia 
 Anaphylactic shock 
P
h
ys
io
lo
gi
c 
 Limited nausea and 
vomiting 
 Transient flushing, 
warmth, chills 
 Headache 
 Dizziness 
 Anxiety 
 Altered taste 
 Mild Hypertension 
 Vasovagal reaction that 
resolves spontaneously 
 Stable vital signs 
 Protracted N/V 
 Hypertensive urgency 
 Isolated chest pain 
 Vasovagal reaction that 
is responsive to 
treatment 
 Vasovagal reaction 
resistant to treatment 
 Arrhythmia  
 Convulsions/seizures 
 Hypertensive emergency 
*Adapted from American College of Radiology Contrast Media Guidelines  
*The term allergic-like is used as these reactions are often not true allergies (i.e. not immune 
mediated) 
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B. Because mild reactions are usually self-limiting, the workgroup does not have specific 
recommendations for routine treatment of mild reactions. The workgroup recommends 
continued evaluation of the patient for potential progression. Delayed reactions are also 
typically self-limiting. The workgroup recommends verbal and written patient education 
about the possibility of delayed reactions and when to seek medical attention. For 
management of moderate or severe CM allergic reactions, the workgroup recommends that 
treatment should be targeted based on the specific reaction a patient is experiencing 
according to Table 3. The following additional reactions may occur and the team should be 
prepared to treat them: arrhythmia, hypertensive crisis, hypoglycemia, pulmonary edema, 
seizures. the workgroup recommends that the patient should be monitored for a minimum of 
4 hours if any medication was given to treat a moderate or severe reaction. The workgroup 
recommends that prior to discharge the patient should be provided with a verbal and 
written emergency plan in the event of a reaction recurrence. Finally, the allergy and a 
description of the severity of the reaction should be documented in the EHR. 
 
Table 3: Treatment of Moderate or Severe Contrast Allergic Reactions  
Reaction Treatmenta 
If any of the following: 
 Diffuse urticaria, pruritus, 
erythema 
 Hypotension  
Administer all of the following: 
 Diphenhydramine 25 to 50 mg IV once 
 Supplemental oxygen  
 0.9% normal saline IV bolus 
If mild bronchospasm Administer the above therapies AND 
Add albuterol 0.083% solution 1 ampule via 
nebulizer q2h prn bronchospasm 
If any of the following: 
 Moderate to severe bronchospasm 
 Laryngeal edema  
 Hypotension that is profound or 
unresponsive to fluids 
Administer the above therapies AND 
Add epinephrine 0.2 mg IM once. May repeat every 
5-15 minutes for persistent severe symptoms 
Add famotidine 20 mg IV once or equivalent 
aThe workgroup recommends that these medications be available as either a physical kit or a 
virtual kit in an automated dispensing cabinet. 
 
3. Management of Patients with a History of a Moderate or Severe Contrast Allergy 
Consensus Statement IV-3 (page 27-28) 
A.   The workgroup recommends that a patient with a history of a moderate or severe contrast 
allergy should be managed according to Figure 1.  
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Figure 1: Management of Patients with a History of Moderate or Severe Contrast Allergy 
History of a moderate or severe 
contrast media reaction
Consider an alternative test or 
procedure. Consultation with 
proceduralist/radiologist recommended
Alternative test/procedure 
appropriate?
Use alternative test/procedure
Minimize contrast media amount, if 
possible. Arrange for monitoring in a 
medical setting for at least 4 hours after 
contrast media administration.
When is test/procedure needed?
1) Methylprednisolone* 125 mg IV STAT, as soon as possible prior 
to contrast media administration.
2) Diphenhydramine 50 mg IV STAT. 
1) Methylprednisolone* 125 mg IV NOW, administered 6 to 12 
hours prior to contrast administration.
2) Diphenhydramine 50 mg IV within 6 hours of contrast medial 
administration. (Redose if contrast media administration is delayed 
>6 hours). 
ORAL
1) Prednisone 20 to 50mg PO at 12 hours, 6 hours, and 1 hour 
prior to contrast media administration. 
2) Diphenhydramine 50 mg PO once within 6 hours of contrast 
media administration. (Redose if contrast media administration 
delayed >6 hours.)
NPO 
1) Methylprednisolone* 125 mg IV once 12 to 24 hours prior to 
contrast administration.
2) Diphenhydramine 50 mg IV  once within 6 hours of contrast 
media administration. (Redose if contrast media 
administration delayed >6 hours.) 
Provide all patients with an 
emergency action plan for 
delayed reactions
Emergent
Non-Emergent
and <12 hours
12 Hours or More
Yes
No
* Alternatively, may give methylprednisolone 
40 mg IV Q4H until contrast administration
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Consensus Statements 
Note: Consensus statements focus on contrast media-induced nephropathy (CIN) in adults from 
intravascular, iodinated contrast media (CM) administration and do not address the following: 1) 
risks associated with iodinated, oral CM or CM administered by other routes; 2) risks associated 
with other agents, including the risk of nephrogenic systemic fibrosis from gadolinium; OR 3) risks 
specific to the pediatric population. 
I. Screening 
I-1 Risk Factors 
 
A myriad of CIN risk factors exist in the literature today, some more widely studied than others. 
While there are over 200 risk factors for CIN identified in published literature, 1-43 the most widely 
accepted include CKD (identified by an eGFR min threshold < 40 ml/min/1.73m2 [minimum 
standard] with data supporting a widened threshold of <60 ml/min/1.73m2), diabetes mellitus, 
congestive heart failure and advanced age (≥ 75 years). Of these, CKD and diabetes mellitus are 
more consistently recognized as risk factors for CIN. 29,33,37,38,41,43  Data also demonstrates that 
congestive heart failure and advanced age (≥ 75 years) are also independently associated with an 
increased risk of CIN. 33,37,39,42,43 These data are summarized in Table 4. Several conditions limit the 
accuracy of CIN risk factors in the current literature: 1) highly variable definitions within the 
related literature for CIN as an outcome; 2) the definitions and thresholds defining specific risk 
factors vary widely among studies; and 3) data outside cardiac catheterization populations are 
limited.  Furthermore, many studies designed to evaluate associated risk of CIN in the presence of 
particular risk factors are performed in patient populations that are already defined by CKD. 33-35 As 
a result, it is not possible to extend the comparisons made in this summary beyond a general 
description of current literature and local practices. 
 
Conclusion 
CKD (identified by an eGFR min threshold < 40 ml/min/1.73m2 [minimum standard] with data 
supporting a widened threshold of <60 ml/min/1.73m2), diabetes mellitus, age 
≥75 years, and congestive heart failure are the most well recognized and literature supported, 
independent risk-factors associated with an increased risk of CIN. While not specifically addressed, 
other additional risk factors identified by the current literature may be important in certain 
situations or populations. 
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Table 4. Measures of Association for CIN Risk Factors 
 
Risk Factor Reference Odds Ratio 95% Confidence Interval 
Renal Insufficiency 
Chronic Kidney disease 
Nikolsky E et al.33 1.51a 1.11 to 2.07 
 Rihal CS et al.38 7.37b 4.78 to 11.39 
 Rihal CS et al.38 12.82c 8.01 to 20.54 
 Mehran R et al.37 1.19d 1.10 to 1.30 
 Mehran R et al.37 2.05e 1.57 to 2.66 
Diabetes Mellitus Nikolsky E et al.33 1.84 1.36 to 2.47 
 Rihal CS et al.38 1.61 1.21 to 2.16 
 McCullough PA et al.41 5.47 1.40 to 21.32 
 Mehran R et al.37 1.60 1.34 to 1.91 
 Bartholomew BA et al.43 3.10 2.30 to 4.20 
Congestive Heart Failure Nikolsky E et al. 33 2.21 1.34 to 3.64 
 Rihal CS et al.38 1.53 1.12 to 2.10 
 Manske CL et al.42 10.0 1.0 to 69.4 
 Mehran R et al. 37 2.70 2.02 to 2.60 
 Bartholomew BA et al.43 2.20 1.60 to 2.90 
Age ≥ 75 years Mehran R et al.37 2.20 1.78 to 2.71 
 Marenzi G et al.39 5.28 1.98 to 14.05 
a Baseline creatinine> 1.5 mg/dL or GFR < 60 mL/min/1.73 m2 b 
Baseline Cr 2.0-2.9 mg/dL (GFR data not available) 
c Baseline Cr ≥ 3.0 mg/dL (GFR data not available) 
d GFR < 60 mL/min/1.73 m2 
e Baseline Cr > 1.5 mg/dL 
 
I-2 Estimated Glomerular Filtration Rate (eGFR) 
 
Conclusion 
The American College of Cardiology (ACC), the American College of Radiology (ACR), the National 
Kidney Disease Education Program (NKDEP), the National Kidney Foundation (NKF) and the 
American Society of Nephrology (ASN) all recommend estimating glomerular filtration rate from 
serum creatinine. While all equations have limitations, the Modification in Renal Disease (MDRD) 
study equation, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), and the 
Cockcroft-Gault equation are all acceptable methods to estimated glomerular filtration rate using 
measured serum creatinine.8 All of these equations use measured serum creatinine in combination 
with sex, weight, or race to estimate glomerular filtration rate. As a result, these equations improve 
upon the limitations of measured serum creatinine alone. 
 
I-3 Selective Assessment of Renal Function 
 
Compulsory creatinine screening and assessment of eGFR to risk-stratify patients for CIN is not 
cost-effective and often time prohibitive, particularly with urgent or emergent procedures.44 The 
ACR recommends selective serum creatinine screening prior to routine intravascular studies for 
patients age >60 years or with a history of any of the following renal disease: dialysis dependence, 
kidney transplant, single kidney, renal cancer, renal surgery, hypertension requiring medical 
therapy, or a history of diabetes mellitus.45 This guideline also recommend serum creatinine 
screening for patients using metformin, but acknowledge that this recommendation is not aimed at 
assessing the risk of CIN, but rather the risk of lactic acidosis.45 Additionally, the ACR guideline 
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classifies serum creatinine screening performed within 30 days is prudent, but acknowledges the 
lack of evidence to support a specific time-frame and supports more timely screening in 
hospitalized patients.45 Finally, the guideline also acknowledges the potential need for exceptions to 
screening for emergent studies and procedures, but does not further specify recommendations for 
creatinine screening in these situations.45 The ACC and the American Heart Association (AHA) 
guidelines are less specific with recommendations for peri-procedural creatinine screening, instead 
recommending the assessment of multiple risk-factors for CIN.46 
 
To improve selective screening with serum creatinine, three studies define screening criteria 
aimed at identifying patients at risk of CKD.44,47,48 In all three studies, the primary outcome 
assessed was the identification of an elevated serum creatinine. The largest of these studies 
includes retrospective data from 2,555 consecutive patients undergoing computed tomography 
(CT) studies with serum creatinine measurements performed within 3 days prior to CM exposure. 
In 94% of these cases  the patient had a history of CKD and 18% had a history of diabetes mellitus 
(insulin dependent diabetes mellitus or non-insulin dependent diabetes mellitus). Concurrent 
chemotherapy and the presence of a solitary kidney were also studied as risk-factors for renal 
insufficiency/CKD, with these factors identifying <1% of cases of renal insufficiency/CKD in the 
absence of either prior CKD or diabetes mellitus. Assessment of all four risk-factors would have 
identified 99% of patients with CKD.44 Choyke et al. studied the accuracy of a patient questionnaire 
administered to 633 consecutive patients undergoing CT. Patients were asked to give a history of 
any of the following: chronic kidney disease proteinuria, hypertension, diabetes mellitus, gout, or 
kidney surgery. The use of this questionnaire identified 70% of patients with CKD and decreased 
the need for serum creatinine testing by 67%.47 These studies are both cited as acceptable means of 
selecting patients for serum creatinine screening by the ACR guideline.45 Finally, Olsen et al. 
measured the prevalence of CKD in 640 patients undergoing iv pyelogram or contrast-enhanced CT 
of the brain or abdomen.48 Combined, the following risk-factors identified 98% of cases of CKD: age 
>60 years, diabetes mellitus, hypertension, congestive heart failure, coronary artery disease, 
and/or liver disease.48 Importantly, all three studies defined renal insufficiency or CKD using a 
serum creatinine threshold (1.5 to 1.8 mg/dL). However, current published evidence supports the 
use of eGFR rather than an absolute serum creatinine threshold.8 Moreover, the primary outcome 
of these studies was limited to the identification of chronic renal dysfunction and none of these 
studies directly measured the outcome of CIN. 
 
Conclusion 
Serum creatinine screening is most strongly supported in patients with a history of renal 
dysfunction and/or diabetes mellitus (both insulin dependent and non-insulin dependent diabetes 
mellitus). While less clearly supported by current literature, serum creatinine screening (and 
assessment of eGFR) in patients with the following conditions appears reasonable: age ≥ 60 years, 
hypertension, congestive heart failure or prior kidney surgery. While there are no data establishing 
a specific time frame, consensus supports the use of serum creatinine measurements within 30 
days in the ambulatory setting and within 48 hours in the inpatient setting. 
 
I-4 Emergency Exception 
 
Conclusion 
National guidelines support emergency exceptions screening for CIN, including serum creatinine 
screening, and pre-exposure treatment. 8,45,46 The following emergent indications for contrast- 
enhanced diagnostic imaging and interventional procedures were identified: 1) ST elevation 
myocardial infarction (STEMI) requiring emergent cardiac catheterization; 2) emergent evaluation 
for thrombolysis for acute cerebral vascular accident (“stroke one” or “code stroke”); 3) acute 
vascular complications requiring emergent intervention such as aortic dissection, aortic aneurysm 
rupture, acute limb ischemia, and mesenteric ischemia; and 4) indications for potentially life or 
limb threatening conditions. In these situations, screening and treatment measures, including 
serum creatinine screening, for CIN that may delay access to emergent diagnostic and 
interventional procedures are of limited benefit. 
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II. Prevention 
II-1 Peri-Procedural Hydration 
 
Conventional hydration protocols have recommended intravenous (IV) hydration prior to CM 
exposure with the aim of decreasing the risk subsequent risk of CIN. These are designed to induce a 
state of mild hypervolemia, thereby increasing renal filtration, in patients presumed to be 
euvolemic at the onset. Recent studies suggest oral hydration may be as efficacious as IV hydration. 
In an early study, oral hydration was shown to be as effective as IV hydration in preventing CIN in 
patients undergoing cardiac catheterization.49 Multiple subsequent studies have demonstrated oral 
hydration is as effective as IV hydration in patients undergoing cardiac procedures with moderate- 
severe baseline renal dysfunction50-52 as well as patients with normal to mildly impaired baseline 
renal function, including two randomized trials.53-55 Conversely, Trivedi et al56 demonstrated IV 
hydration is more effective than oral hydration in patients undergoing cardiac catheterization in a 
prospective, randomized controlled trial where the study instructed patients in the oral intake arm 
to “increase fluid intake” unmonitored and without a protocol. The potential safety of oral versus IV 
hydration is of particular concern in volume sensitive patients. However, only two studies have 
specifically addressed this question. Lee et al57 demonstrated a non-significant trend of increased 
pulmonary edema and pleural effusions in patients undergoing IV fluid replacement. Agoulvant et 
al53 observed no IV hydration-induced pulmonary edema in patients with impaired left ventricular 
function.  With all of these studies, the volume and time of administration and follow-up vary 
widely, and data comparing IV to oral fluid administration are particularly limiting in settings 
where hydration administered over several hours is impractical. There are no studies 
demonstrating the effectiveness of oral hydration initiated after CM exposure, nor are there studies 
evaluating an additive benefit of oral hydration as an adjuvant to IV hydration. Finally, there are no 
studies demonstrating the effectiveness of either oral or IV fluid administration in hypovolemic 
patients or patients exposed to CM following any period of fluid restriction. Outside of CIN, oral 
hydration has been shown to be as beneficial as IV hydration in fluid replacement therapy in 
patients with dengue hemorrhagic fever57 and dehydration.58 Transient hydronephrosis has also 
been observed ultrasonically following rapid oral fluid administration. Studies of oral hydration 
were conducted in the setting of causes of extreme hypovolemia and dehydration. Close monitoring 
of adequate intake and active patient instruction occurred. There are no studies demonstrating the 
effectiveness of simplified instructions allowing ad lib oral fluid intake. Notably, there are no 
studies demonstrating either increased CM retention with hypovolemic states nor data directly 
demonstrating volume- induced changes renal CM elimination.59 
 
Conclusion 
Sufficient data exist to support protocol-driven oral hydration initiated 12 to 24 hours prior to CM 
exposure. Although oral hydration may offer additional safety for volume-sensitive patients, data 
are not sufficient to demonstrate the efficacy of oral hydration alone or as an adjuvant to IV 
hydration in these populations specifically. All data are limited to patients whose exposure to 
iodinated CM occurs in the setting of cardiac catheterization. There are no data specifically 
examining oral hydration following single-bolus IV administration, which may have some 
differential effect. Similarly, oral hydration initiated immediately prior to or after CM exposure or 
in hypovolemic patients has not been studied. 
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NPO After Procedure? 
Yes No 
IV Hydration 
As Indicated 
≥750mL Oral Fluids Over Next 24 Hours 
Adjust volume for patient tolerance†‡ 
NPO After Procedure? 
Yes No 
IV Hydration 
As Indicated 
≥1500mL Oral Fluids Over Next 24 Hours 
Volume Sensitive? 
Yes No 
NPO Prior to Procedure? NPO Prior to Procedure? 
Yes No Yes No 
Figure 2.  Recommended peri-procedural hydration guideline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Initiation of intravenous hydration with normal saline is recommended prior to, but may be completed after CM administration. 
† This guideline is intended as a recommendation only and should be adjusted as clinically indicated. Consultation with the referring or treating provider is 
recommended. 
‡ Consider holding loop diuretics starting 12 hours prior to CM administration, in volume-sensitive patients on chronic loop diuretic therapy who are unable to 
tolerate IV hydration.
Peri-Procedural Hydration* 
≥750mL IV over ≤4 hours 
Adjust Volume and Rate for Patient Tolerance†‡ 
Peri-Procedural Hydration* 
≥500mL IV over ≤2 hours 
Adjust Volume and Rate for Patient Tolerance†‡ 
   
  
 
Peri-Procedural Hydration* 
≥1000 mL IV over ≤2 hours 
Peri-Procedural Hydration* 
≥500mL IV over ≤2 hours 
   
  
 
Increased risk of CIN? 
Consensus Statements I-01, I-02 and I-03 
Yes 
No Consider Reduced Contrast Load 
and/or Non-Contrast Alternatives 
Consultation with Radiologist or Interventionalist Encouraged 
IV and/or Oral Hydration 
Encouraged 
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II-2 N-Acetylcysteine 
 
Prophylactic use of IV and oral N-acetylcysteine (NAC) for the prevention of CIN has been examined 
for over ten years, yet evidence examining efficacy remains inconclusive.  The first trial, published 
in 200060, demonstrated a 90% reduction in the incidence of CIN with prophylactic NAC treatment. 
Subsequent studies have demonstrated mixed results. Eight randomized controlled trials were 
reviewed to examine the efficacy of prophylactic NAC in patients undergoing cardiac angiography, 
angioplasty, or intra-operative CM exposure: seven concluded prophylactic NAC has no additional 
benefit compared the placebo or normal saline hydration groups61-66 and one concluded IV NAC 
reduces the rate of CIN in a dose-dependent manner67. A single randomized controlled trial, 
published in abstract format, studied IV NAC administered as a 6 hour infusion initiated 1 hour 
prior to CT, did not demonstrate a benefit to NAC administration in addition to IV hydration.68 Eight 
meta-analyses were also examined: five concluded prophylactic NAC is beneficial in reducing CIN69-
73 and three concluded the effect of NAC is inconclusive74-76. However, all meta- analyses reporting 
benefit and all but one reporting inconclusive findings77 were significantly limited by significant 
statistical heterogeneity. There are no published data demonstrating the benefit of NAC as an 
alternative to hydration in volume-sensitive patient populations. 
 
Conclusion 
The prophylactic administration of IV or oral NAC is of limited effectiveness compared to hydration 
alone in the prevention of CIN. This recommendation is based on both the preponderance and 
strength of evidence evaluated in patients undergoing cardiac catheterization. There are 
insufficient data to support a recommendation for or against the use of NAC as an alternative to 
hydration, for patients exposed to CM outside of cardiac catheterization, or as a substitute for use in 
volume-sensitive patients. 
 
II-3 Sodium Bicarbonate 
 
Multiple meta-analyses were reviewed to examine the effect of prophylactic administration of 
sodium bicarbonate in the prevention of CIN. These meta-analyses analyzed between four78 and 
eighteen79 controlled trials. Overall, the majority of meta-analyses concluded that there is some 
benefit to an infusion of sodium bicarbonate in decreasing the incidence of CIN, although with small 
effect size. Notably, some controlled trials included in these meta-analyses combined 
administration of sodium bicarbonate with NAC in the treatment arm, complicating the ability to 
draw conclusions on the effect of sodium bicarbonate alone in the prevention of CIN. However, all 
meta-analyses78-86 were limited by significant statistical and population heterogeneity. Only two 
analyses addressed statistical and population heterogeneity.79,86 Hoste et al79 demonstrated 
borderline effect size and significance of sodium bicarbonate in the prevention of CIN in patients 
undergoing cardiac procedures. However, the benefit of sodium bicarbonate was eliminated when 
cardiac and non-cardiac procedures were combined. Brar et al86 separated their analysis into large 
(n ≥ 290) and small (n ≤ 290) trials.  In doing so, statistical heterogeneity was minimized in the 
large trial analysis resulting in no observed benefit to sodium bicarbonate. 
 
Data supporting the use of sodium bicarbonate in preference to saline hydration in volume- 
sensitive populations are extremely limited. We were only able to identify a single randomized 
controlled trial (n=72), which did not demonstrate any difference in the incidence of CIN or in 
complications from hypervolemia among patients receiving sodium bicarbonate compared to 
those hydrated with IV saline alone.87 
 
Conclusion 
The benefit of sodium bicarbonate in preventing CIN demonstrated in several meta-analyses is 
limited by statistical and population heterogeneity. In a meta-analysis supported by large 
prospective studies, where statistical heterogeneity is addressed, the benefit if sodium bicarbonate 
is no longer observed.9 There may be some benefit, although with a small effect size, specifically in 
patients undergoing cardiac catheterization, but this benefit is no longer observed when data are 
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combined with patients exposed to CM outside of cardiac catheterization.2 
 
II-4 Post-Procedural Dialysis 
 
Many in vitro and in vivo studies have demonstrated the efficient removal of intravascular CM via 
hemodialysis, yet evidence suggests hemodialysis does not significantly reduce the incidence of 
CIN. Three reviews, one meta-analysis, and eight prospective studies were evaluated to determine 
the effect of hemodialysis on the incidence of CIN after CM administration, largely in the setting of 
cardiac procedures. All three reviews88-90 concluded hemodialysis does not significantly reduce the 
incidence of CIN. The one meta-analysis91 reviewed also concluded hemodialysis does not 
significantly reduce CIN (no statistical heterogeneity for hemodialysis). Seven of the prospective 
studies92-98 demonstrated hemodialysis does not significantly reduce the incidence of CIN after CM 
administration in patients with chronic kidney disease. Vogt et al93 suggests hemodialysis may 
even be harmful. Only one of the prospective studies99 demonstrated a significant reduction in the 
incidence of CIN following post-exposure hemodialysis. There are no definitive data to support 
alterations in either the timing of regularly scheduled dialysis with respect to CM exposure or the 
timing of CM exposure with respect to regularly scheduled dialysis. Studies were limited by 
significant heterogeneity with respect to populations studied, the hemodialysis protocol utilized, 
and the concurrent use of adjuvant prophylactic therapies such as saline hydration and NAC. 
 
Conclusion 
Post-exposure hemodialysis for the prevention of CIN in patients with chronic kidney disease is of 
limited effectiveness. This recommendation is based on a preponderance of published studies 
demonstrating a lack of effectiveness and one study demonstrating the potential for harm. These 
studies are limited by significant heterogeneity. 
 
II-5 Iso-Osmolar Contrast Media 
 
Currently, the only commercially available non-ionic, iso-osmolar, iodinated CM is iodixanol 
(Visipaque). The osmolarity of this agent is 290 mOsm/kg compared to 470 to 670 mOsm/kg for 
low-osmolar agents. A second agent, iotrolan (Isovist) has an osmolarlity of 320 mOsm/kg, but is 
less well studied and is a more expensive agent than even iodixanol. Studies have compared the 
incidence of CIN following iodixanol to that associated with the administration of the following non- 
ionic, low-osmolar CM (LOCM) agents: ioxaglate (Hexabrix), iopamidol (Isovue), iohexol 
(Omnipaque), iomeprol (Iomeron), and iopromide (Ultravist). Early studies demonstrated 
inconclusive outcomes when comparing iodixanol to LOCM. 100-102 The results of subsequent 
randomized controlled trials are variable. The NEPHRIC trial demonstrated a significant reduction 
in CIN in 129 patients with both chronic renal disease and diabetes undergoing cardiac 
catheterization randomized to iodixanol versus iohexanol (serum creatinine increase ≥ 0.5 mg/dL, 
3% with iodixanol versus 26% with iohexanol, p<0.05).103 In a larger study of 414 patients with 
CKD, the CARE trial compared iodixanol to iopamidol. The rates of post-cardiac catheterization CIN 
were not statistically distinguishable: serum creatinine increase ≥ 0.5 mg/dL, 6.7% for iodixanol 
and 4.4% for iopamidol, p = 0.39; serum creatinine increase ≥ 2 5 % from baseline, 12.4% for 
iodixanol and 9.4% for iopamidol, p = 0.44.104 We also reviewed the results of 5 smaller randomized 
controlled trials comparing LOCM agents in patients undergoing contrast-enhanced CT and/or 
cardiac catheterization procedures: two studies concluded iodixanol was significantly less 
nephrotoxic than ioxaglate105 and to iopromide106, two studies concluded iodixanol was not 
associated with a statistically significant reduction in the incidence of CIN compared to LOCM 
agents tested individually 107,108, and one study concluded the incidence of CIN was significantly 
higher with iodixanol than with iomeprol109. Three of four meta-analyses concluded that iodixanol 
does not significantly reduce the incidence of CIN when compared to LOCMs (pooled result) in 
patients with CKD.110-112 However, these three studies do report a modest, but statistically 
significant reduction in CIN with iodixanol compared to iohexol, but not with other agents. 110-112 
One meta-analysis concluded iodixanol significantly reduces the incidence of CIN in patients with 
chronic kidney disease and diabetes mellitus when compared to other LOCM agents.113 Notably, the 
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manufacturer of iodixanol sponsored this study and supplied the data. Aspelin et al. demonstrated 
that despite a 20% difference in cost, the use of iodixanol was cost- effective compared to 
iohexanol.114 However, when the same cost-benefit analysis methods were applied using data from 
the CARE trial, the use of iopamidol had a comparatively larger cost-benefit compared to iodixanol, 
even among high-risk patients.115 
 
While not directly affecting the issue of CIN, there are some experts who recommend stocking iso- 
osmolar agents, in addition to LOCM agents specifically for oral or bronchial administration, 
because of a potential for decreased risk with aspiration. There are data demonstrating increased 
safety with the use of LOCM for off-label oral administration compared to high-osmolar agents and 
barium. 116 The safety of iotrolan, but not iodixanol, with bronchial introduction has been studied 
and appears to be similar to that of LOCM agents.117 There are no published data demonstrating an 
advantage with respect to the risk of aspiration of an iso-osmolar agent compared to other LOCM. 
 
Conclusion 
Published data does not demonstrated a consistent therapeutic benefit or a cost-effectiveness 
benefit supporting the use of iso-osmolar CM agents as an alternative to contemporary low-osmolar 
CM agents for the prevention of CIN. 
 
II-6 Cessation of Concurrent Medications 
 
The development of CIN as an outcome of CM exposure combined with the use of certain renal or 
nephrotoxic medications deserves attention. Potentially nephrotoxic medications of concern 
include, but are not limited to: diuretics, nephrotoxic antibiotics (gentamicin and tobramycin), non- 
steroidal anti-inflammatory drugs (NSAID), antihypertensive agents (angiotensin converting 
enzyme inhibitors [ACEi] and angiotensin receptor blockers [ARB]), chemotherapeutic agents, and 
specifically, tenofovir, colchicine, and amphotericin B. Limited evidence regarding these 
medications and their effects on the development of CIN exists in the medical literature.  Neither 
the ACR nor the ACC/AHA have published recommendations for either discontinuation or dose 
modification of these medications.45,46 
 
Furosemide (Lasix), torsemide (Demadex), bumetanide (Bumex), spironolactone (Aldactone), and 
acetazolamide (Diamox) are diuretics that were included in our literature search. Effects of these 
medications on the development of CIN are largely ambiguous. Four randomized controlled 
trials50,118-120 evaluating furosemide and CM concluded that furosemide did not effectively reduce 
the incidence of CIN. Two trials concluded furosemide effectively prevents the development of CIN 
if high urine output is achieved through matched hydration.121,122 Contrarily, three of the four 
studies further concluded that furosemide has the potential to increase the risk of developing CIN 
after CM exposure.118-120 Of note, mannitol was included in three of the studies addressing 
furosemide.118,119,122 The observed effects of mannitol were the same as furosemide in the 
respective studies. Only one study was identified for acetazolamide and suggested the risk of CIN 
development is reduced with acetazolamide.123 No studies were identified for the other diuretics 
included in the literature search. 
 
Of the antihypertensive agents, benzapril, captopril, cilazapril, enalapril, fosinopril, lisinopril, 
moexepril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, 
irbesartan, losartan, olmesartan, telmisartan, and valsartan were included in our literature search. 
Only one study was identified for these medications, and it addressed the effect of captopril on the 
development of CIN.124 The study concluded captopril reduces the risk of developing CIN after CM 
exposure in the diabetic population.124 No studies were identified for the other antihypertensive 
medications. 
 
No studies were identified for any of the other medications or classes of drugs: NSAIDs (ibuprofen, 
naproxen, toradol, celecoxib, and indomethacin), chemotherapeutic agents (cisplatin, carboplatin, 
bendamustin, cyclophosphamide, streptazocin, mitomycin C, bleomycin, methotrexate, vincristine, 
P a g e  | 22 
 
vinblastine, topotecan, interleukin 2 and interferon), tenofovir, colchicine, and amphotericin B. 
 
Conclusion 
There is little evidence in current medical literature to support a recommendation guiding the use 
of the medications reviewed by this committee with intravascular iodinated CM exposure. Though 
multiple studies addressing the effect of furosemide and other loop diuretics on the development of 
CIN exist, conflicting conclusions prohibit the development of a specific guideline recommending 
that patients either continue or discontinue furosemide prior to CM exposure. However, in patient 
on chronic furosemide, who are unable to tolerate intravenous hydration, withholding loop 
diuretics 12 hours prior to CM administration should be considered. 
 
II-7 Metformin 
 
It is well-recognized that metformin use, alone or as part of combination therapy, does not increase 
the risk of CIN. However, current package inserts approve by the US Food and Drug administration 
recommend temporarily discontinuing the use of metformin after the administration of 
intravascular CM. 
(http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf, 
accessed 08/12/13) This recommendation is based on the potential for patient to develop lactic 
acidosis as a result of developing CIN and subsequently decreased lactic acid metabolism. The 
occurrence of lactic acidosis resulting from metformin use in the setting of CIN is extremely rare. In 
fact, there are no published accounts of CIN-related, metformin-induced lactic acidosis with 
contemporary nonionic, low-osmolar agents. In fact, nearly all cases of non-CIN related metformin- 
induced lactic acidosis have occurred in patients with co-morbid conditions that result in either 
increased production or decreased metabolism of lactic acid: liver disease, advanced kidney 
disease, and conditions associate with regional or global hypoperfusion and/or shock including 
cardiac failure, sepsis, hemorrhage, vascular occlusion, etc.). These conditions are independent 
contraindications to metformin use. 
(http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdf, 
accessed 08/12/13) Over the past decade, the prevalence of metformin use has increased 
significantly, as has the use of metformin in general, and for treatment of conditions outside of type 
2 diabetes mellitus.125,126 
 
The ACR recommends the discontinuation of metformin only in patients with known renal 
dysfunction and those with: liver disease, alcohol abuse, cardiac failure, myocardial or peripheral 
muscle ischemia, and/or sepsis or severe infection. Furthermore, the ACR guideline recommends 
that metformin can be resumed after 48 hours in patients without known renal dysfunction (at the 
time of CM administration) and have not had the intercurrent development of risk factors for acute 
kidney injury. In patients with known renal dysfunction, the guideline recommends “cautious 
follow-up until safe restitution of metformin can be assured.” Discontinuation of metformin is not 
recommended in patients without these conditions.45 
 
The ACC and the Society for Cardiovascular Angiography and Interventions (SCAI) recommend 
discontinuation of metformin on the day of the CM administration for routine, non-emergent 
percutaneous coronary angiography procedures and 48 hours after CM administration for all 
procedures, with resumption of metformin only after documentation of stable renal function.127 
This recommendation may reflect the increased prevalence of conditions that increase the risk of 
acute kidney injury or that disrupt lactic acid metabolism in this population. However, the strength 
of this recommendation remains controversial, with some studies demonstrating improved 
outcomes with continued metformin administration after coronary angiography.128 
 
Conclusion 
Metformin use does not increase the risk of CIN. Rarely, the risk of lactic acidosis may be increased 
in patients that develop CIN while taking metformin. For percutaneous coronary angiography, 
national guidelines currently recommend the discontinuation of metformin starting the day of the 
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non-emergent procedures continuing for at least 48 hours after all procedures. Reassessment of 
renal function is currently recommended prior to resuming metformin use. However, in some 
select cases, continued metformin use may be indicated. For radiologic studies and procedures 
involving CM administration, national guidelines recommend the discontinuation of metformin for 
a minimum of 48 hours after CM administration in patients with known chronic kidney disease or 
those with liver disease, alcohol abuse, cardiac failure, myocardial or peripheral muscle ischemia, 
and/or sepsis or severe infection. In patients with conditions that may result in acute kidney 
injury, assessment of renal function and risk of progressive renal dysfunction are also 
recommended prior to resuming metformin use. 
 
II-8 Minimizing Contrast Media Exposure 
 
CT imaging without CM or alternative imaging modalities such as ultrasound or magnetic resonance 
imaging (MRI) are recommended for an increasingly wider spectrum of clinical indications. 
(American College of Radiology. ACR Appropriateness Criteria®. Available at www.acr.org/ac 
Accessed 3/26/2014) Similarly, national guidelines recommend approaches to conserve CM 
exposure for diagnostic and therapeutic peripheral vascular and cardiovascular procedures for 
patients at increased risk of CIN. 129-131 Given the current state of available technologies and 
expertise currently available across healthcare institutions represented within the Contrast Media 
Workgroup, both the ACR Appropriateness Criteria® and the ACCF/AHA Guidelines represent 
potential opportunities to create a guideline to limit unnecessary CM exposure that can be reliably 
applied across institutions in the Indianapolis region. 
 
However, CM remains integral to the diagnosis and management for many clinical indications for 
which there are currently no viable alternatives. Moreover, communication between the referring 
physician and the radiologist, cardiologist or other interventionalist is critical to identifying specific 
cases where reduced-CM or non-CM alternatives are appropriate. 
 
Recent advances in contrast-enhanced CT imaging have resulted in methods to reduce CM dose for 
specific imaging indications. Such protocols are particularly valuable in cases where alternatives to 
contrast-enhanced CT imaging are not viable, especially in patients at increased risk of CIN. The 
workgroup has reviewed the experience of local institutions with reduced dose CT imaging 
protocols that leverage high resolution CT scanners and with software that allows for adjusted CM 
dosing.   Notably, not all institutions or affiliated sites (e.g. outpatient, free-standing imaging 
centers) are able to offer reduced-CM protocols because of equipment or other technologic 
restrictions. Furthermore, the reliability and reproducibility of these methods appear to vary 
significantly from institution to institution and even site to site. In some cases, inconsistent image 
quality resulting in the need for repeat imaging, may conversely result in increased patient 
exposure to CM. At this time, the workgroup was unable to identify specific reduced-CM protocols 
that can be reliably applied on a regional basis. However, as these techniques undergo further 
development, the workgroup anticipates that regional institutions will be able to adopt reduced-CM 
protocols with increasing frequency in the near future. 
 
Conclusions 
1) The workgroup recommends recurring institution and site-level reviews of imaging and 
interventional protocols for adherence to the ACR Appropriateness Criteria® and 
ACCF/AHA Guidelines, with specific attention to the inclusion of protocols that reduce or 
eliminate CM exposure in patients at increased risk of CIN. 
2) The workgroup supports institutional efforts to identify and evaluate emerging imaging or 
interventional techniques that avoid or limit CM exposure in patients at increased risk of 
CIN. 
3) The work group supports the referral of selected patients at increased risk of CIN requiring 
CM to institutions or sites where appropriate non-CM or reduced-CM alternatives are 
performed with demonstrated reliability. 
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III. Electronic Health Record (EHR) 
III-1 Reporting Contrast Media Administration 
 
Creating the ability within an EHR to easily query recent exposure, prior to the administration of 
additional CM,  provides a safer framework when ordering CM, potentially avoiding excess 
exposure and allowing providers to make more fully informed decisions. The ability to query CM 
administration in a central, single location within the EHR presents unique challenges because CM 
is administered in multiple settings (operating rooms, cardiac catheterization suites, interventional 
radiology, diagnostic radiology, etc.). Additionally, each of these settings has varying methods of 
recording CM administration, including separate electronic record systems. It is the consensus of 
the workgroup that referring providers and the radiologist, cardiologist or other interventionalist 
be made aware of exposures to CM within one week from any setting within an institution 
(including associated outpatient locations), before additional exposures for non-emergent 
indications. 
 
The workgroup does recognize that the introduction of additional steps that require multiple and 
repetitive entries into various systems is likely to introduce unintended opportunities for error, 
have poor compliance and may interfere with the high throughput required to provide diagnostic 
and interventional procedures within our medical community. The workgroup has reviewed the 
EHR systems, including engagement of EHR system managers and technologists, for the 
represented intuitions. We recommend the development of interfaces linking the central EHR and 
existing setting-specific electronic systems. These interfaces should allow for an automatic entry of 
contrast administration events into a single location in the central EHR, minimizing additional re- 
entry by end users. 
 
Importantly in cooperation with the ICPS Medication Safety Workgroup, this workgroup reviewed 
many regulatory issues including the need for a separate provider order, pharmacy reconciliation 
and technologist administration of CM. Individual institutions represented within the workgroup 
have successfully initiated documentation of CM administration in the electronic medication 
administration record (eMAR). These institutions have established CM administration protocols 
that function in lieu of case-by-case, provider-initiated medication orders (“er protocol” orders). 
These protocols specify the administration of CM by the appropriate providers, nurses, and/or 
technologists for diagnostic imaging and interventional procedures in a range of inpatient and 
outpatient settings, and have created processes for post-hoc pharmacy review and reconciliation 
(“auto-verification”). In the case of CM, the ICPS Medication Safety Workgroup supports these 
processes, which are compliant with external regulatory requirements. 
 
Conclusion 
1) The workgroup recommends recording of intravascular CM administration, including date, 
type/concentration, volume, route of administration, and location, within the EHR. 
2) The workgroup recommends the development of interfaces with the central EHR and 
existing setting-specific electronic systems. These interfaces should allow for shared 
information by an automatic entry into the central EHR and should minimize need for 
additional re-entry by end users. 
 
III-2 Computerized Physician Order Entry (CPOE) 
 
The Contrast Media Workgroup has determined that communication barriers contribute to missed 
opportunities to limit or avoid intravascular CM exposures in patients at increased risk of CIN. The 
workgroup also recognizes that the nature of cardiovascular, interventional radiology and other 
interventional procedures is more conducive to direct patient evaluation and identification of 
patients at increased risk. However, in the diagnostic radiology setting, opportunities for direct 
patient evaluation and risk assessment are significantly limited and rely heavily on information 
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from referring providers. At the same time, the pool of referring providers is extremely large and 
heterogeneous with respect to knowledge of CIN risk, preventive therapies and/or the selection of 
alternative or adapted imaging strategies.  Notably, the overwhelming majority of patient 
exposures to intravascular CM agents occur in the diagnostic radiology setting, underscoring the 
importance of improving opportunities for direct communication between referring physicians and 
radiologists. 
 
The introduction of EHR and computer physician order-entry (CPOE) systems has also impacted 
communication with diagnostic radiologists. Traditionally, written orders for diagnostic imaging 
tests were structured around clinical indications that were closely matched to imaging protocols 
that were regularly reviewed at the institutional level and identified when CM was needed. 
Recurring review of institutional imaging protocols also allowed for adaptations to these protocols 
in response to national guidelines and technologic advances. Now, current systems often require 
referring providers to request the administration of CM without additional guidance. Moreover, the 
use of provider-defined order templates (e.g. “favorites”) and the use of limited menus of diagnostic 
or procedural codes also limit the opportunity to communicate patient-specific information. 
Expanding patient volumes, throughput demand, and variability in referring sources also 
contribute to communication barriers, underscoring the need for specific, targeted actions to 
improve communication. The workgroup also identified significant opportunities to leverage the 
EHR and CPOE systems available at regional institutions represented by the workgroup. 
 
Conclusion 
1) When the use of intravascular iodinated CM is planned for non-emergent cardiovascular, 
interventional radiology or other interventional procedures, the pre-procedural patient 
evaluation should include specific screening for risk factors for CIN (consensus statements 
I-01, I-02, I-03 and I-04) and for exposure to CM exposure within 1 week (consensus 
statement III-01). In cases where the interventionalist is not directly assessing these factors, 
institutions should identify specific processes for communicating the presence of one or 
more CIN risk-factors to the interventionalist performing the procedure. 
2) For diagnostic radiology imaging studies, institutions should develop targeted, automatic 
alerts that can be integrated in CPOE systems. Such alerts should be generated based on 
information available in the EHR (e.g. problem lists, medication records, etc.). The alert 
should provide the following information to the ordering/referring provider: 1) that the 
patient is at increased risk of CIN; and 2) Real-time contact information for the appropriate 
diagnostic radiologist(s). Institutions should also have a process for ensuring that contact 
information is correct, up-to-date, and includes backup contacts. 
3) The workgroup recommends that each CPOE order structure for diagnostic radiology 
imaging studies should prompt the ordering/referring provider to describe the specific 
clinical indications and/or clinical concern(s) for the study. General procedural or 
diagnostic code categories do not meet this recommendation. 
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IV. Management of Intravenous Contrast Media Extravasation and Allergic 
Reactions132 
 
IV-1 Extravasation 
 
Patients may complain of swelling, tightness, stinging or burning at the extravasation site. 
Additionally the site may appear edematous, erythematous, and be tender to palpation. For 
management, the workgroup recommends elevating the affected extremity above the level of the 
heart, application of cold compresses, and frequent clinical assessments for several hours after an 
extravasation. The workgroup does not recommend aspiration of the extravasated contrast media 
and does not recommend local injection of corticosteroids or hyaluronidase based on a lack of 
evidence of efficacy. Finally, the extravasation event and any treatments should be documented in 
the EHR. 
 
IV-2 Allergic Reactions 
 
For classification of reactions, the workgroup recommends appropriate assessment of contrast 
reactions as treatments and level of care are determined based on the classification of the reaction. 
Unlike most medication allergy classifications, both moderate and severe contrast allergic reactions 
may require intervention. Refer to Table 1 for descriptions of allergic reaction presentations. 
Delayed adverse reactions most commonly present as urticarial, a persistent rash, or generalized 
exanthematous pustulosis. Non-cutanous reactions include nausea, vomiting, fever, drowsiness, and 
headache. Severe delayed reactions are rare.  
 
Table 2: Contrast Allergic Reaction Presentations 
 Mild Moderate Severe 
A
ll
er
gi
c-
L
ik
e*
 
 Limited: urticaria, 
pruritus, cutaneous 
edema, itchy/scratchy 
throat 
 Nasal congestion 
 Sneezing, 
conjunctivitis, 
rhinorrhea 
 Diffuse: urticaria, 
pruritus, erythema 
 Facial edema without 
dyspnea 
 Throat tightness or 
hoarseness without 
dyspnea 
 Wheezing, 
bronchospasm with mild 
to no hypoxia 
 Diffuse edema or facial 
edema with dyspnea 
 Diffuse erythema with 
hypotension 
 Laryngeal edema with 
stridor and/or hypoxia 
 Wheezing, bronchospasm  
 Significant hypoxia 
 Anaphylactic shock 
P
h
ys
io
lo
gi
c 
 Limited nausea and 
vomiting 
 Transient flushing, 
warmth, chills 
 Headache 
 Dizziness 
 Anxiety 
 Altered taste 
 Mild Hypertension 
 Vasovagal reaction 
that resolves 
spontaneously 
 Stable vital signs 
 Protracted N/V 
 Hypertensive urgency 
 Isolated chest pain 
 Vasovagal reaction that 
is responsive to 
treatment 
 Vasovagal reaction 
resistant to treatment 
 Arrhythmia  
 Convulsions/seizures 
 Hypertensive emergency 
*Adapted from American College of Radiology Contrast Media Guidelines132 
*The term allergic-like is used as these reactions are often not true allergies (i.e. not immune mediated) 
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Because mild reactions are usually self-limiting, the workgroup does not have specific 
recommendations for routine treatment of mild reactions. The workgroup recommends continued 
evaluation of the patient for potential progression. Delayed reactions are also typically self-limiting. 
The workgroup recommends verbal and written patient education about the possibility of delayed 
reactions and when to seek medical attention. For management of moderate or severe CM allergic 
reactions, the workgroup recommends that treatment should be targeted based on the specific 
reaction a patient is experiencing according to Table 3. The following additional reactions may occur 
and the team should be prepared to treat them: arrhythmia, hypertensive crisis, hypoglycemia, 
pulmonary edema, seizures. the workgroup recommends that the patient should be monitored for a 
minimum of 4 hours if any medication was given to treat a moderate or severe reaction. The 
workgroup recommends that prior to discharge the patient should be provided with a verbal and 
written emergency plan in the event of a reaction recurrence. Finally, the allergy and a description of 
the severity of the reaction should be documented in the EHR. 
 
Table 3: Treatment of Moderate or Severe Contrast Allergic Reactions  
Reaction Treatmenta 
If any of the following: 
 Diffuse urticaria, pruritus, 
erythema 
 Hypotension  
Administer all of the following: 
 Diphenhydramine 25 to 50 mg IV once 
 Supplemental oxygen  
 0.9% normal saline IV bolus 
If mild bronchospasm Administer the above therapies AND 
Add albuterol 0.083% solution 1 ampule via 
nebulizer q2h prn bronchospasm 
If any of the following: 
 Moderate to severe 
bronchospasm 
 Laryngeal edema  
 Hypotension that is profound or 
unresponsive to fluids 
Administer the above therapies AND 
Add epinephrine 0.2 mg IM once. May repeat every 
5-15 minutes for persistent severe symptoms 
Add famotidine 20 mg IV once or equivalent 
aThe workgroup recommends that these medications be available as either a physical kit or a 
virtual kit in an automated dispensing cabinet. 
 
IV-3 Management of Patients with a History of a Moderate or Severe Contrast 
Allergy 
 
The workgroup recommends that a patient with a history of a moderate or severe contrast allergy 
should be managed according to Figure 1 
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Figure 1: Management of Patients with a History of Moderate or Severe Contrast Allergya 
 
History of a moderate or severe 
contrast media reaction
Consider an alternative test or 
procedure. Consultation with 
proceduralist/radiologist recommended
Alternative test/procedure 
appropriate?
Use alternative test/procedure
Minimize contrast media amount, if 
possible. Arrange for monitoring in a 
medical setting for at least 4 hours after 
contrast media administration.
When is test/procedure needed?
1) Methylprednisolone* 125 mg IV STAT, as soon as possible prior 
to contrast media administration.
2) Diphenhydramine 50 mg IV STAT. 
1) Methylprednisolone* 125 mg IV NOW, administered 6 to 12 
hours prior to contrast administration.
2) Diphenhydramine 50 mg IV within 6 hours of contrast medial 
administration. (Redose if contrast media administration is delayed 
>6 hours). 
ORAL
1) Prednisone 20 to 50mg PO at 12 hours, 6 hours, and 1 hour 
prior to contrast media administration. 
2) Diphenhydramine 50 mg PO once within 6 hours of contrast 
media administration. (Redose if contrast media administration 
delayed >6 hours.)
NPO 
1) Methylprednisolone* 125 mg IV once 12 to 24 hours prior to 
contrast administration.
2) Diphenhydramine 50 mg IV  once within 6 hours of contrast 
media administration. (Redose if contrast media 
administration delayed >6 hours.) 
Provide all patients with an 
emergency action plan for 
delayed reactions
Emergent
Non-Emergent
and <12 hours
12 Hours or More
Yes
No
* Alternatively, may give methylprednisolone 
40 mg IV Q4H until contrast administration
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